Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

Benzinga · 2d ago
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.